Zhou Bo-rong, Xu Zhi-qiang, Liu Zi-fan
Department of Neurology, the Third Hospital Affiliated to Guangzhou Medical College, Guangzhou.
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2008 Sep;28(9):797-800.
To observe the clinical value of protoparaxotril saporlirs (PTS) combined with aspirin in the secondary prevention of cerebral infarction.
The 140 patients with cerebral infarction were collected, among them the 120 patients during recovery stage were equally assigned to three groups by randomized, single blinded and open controlled principle, and they were treated respectively by PTS (A), aspirin (B), and PTS plus aspirin (C) for 6 months. The other 20, who couldn't or were unwilling to use aspirin, were arranged in group D for control. The platelet aggregation rate, incidence of stroke recurrence, gastrointestinal adverse reaction and the NIHSS scores of patients were observed during the six-month period of treatment.
As compared with group D, the lowering amplitude of platelet aggregation rate after treatment in the three treatment groups were significantly higher (P < 0.01). Comparison of platelet aggregation rate between group A and B showed significant difference after 3-month treatment (P < 0.05), but the difference became insignificant after 6-month treatment (P > 0.05). The incidence of stroke recurrence in the group A, B and C was 18.9%, 13.2% and 10.8% respectively, which showed no significant difference among them, but all were significantly lower than that in the group D (44.4%, P < 0.05). NIHSS scores in group A and C were significantly lower than in group B (P < 0.01); and the occurrence of gastrointestinal reaction was significantly lower in group A (P < 0.01).
Long-term application of PTS has the effects for preventing stroke recurrence, lowering gastrointestinal adverse reaction and improving patients' neural function in patients with stroke. As used in combination with aspirin, it shows potential practical importance in the clinical secondary prevention of stroke.
观察原人参三醇皂苷（PTS）联合阿司匹林在脑梗死二级预防中的临床价值。
收集140例脑梗死患者，其中120例处于恢复期的患者按随机、单盲、开放对照原则分为三组，分别给予PTS（A组）、阿司匹林（B组）、PTS联合阿司匹林（C组）治疗6个月。另外20例不能或不愿使用阿司匹林的患者作为D组对照。观察治疗6个月期间患者的血小板聚集率、卒中复发率、胃肠道不良反应及美国国立卫生院神经功能缺损评分（NIHSS）。
与D组比较，三个治疗组治疗后血小板聚集率下降幅度均显著更高（P<0.01）。A组与B组治疗3个月后血小板聚集率比较差异有统计学意义（P<0.05），但治疗6个月后差异无统计学意义（P>0.05）。A组、B组和C组的卒中复发率分别为18.9%、13.2%和10.8%，三组间差异无统计学意义，但均显著低于D组（44.4%，P<0.05）。A组和C组的NIHSS评分显著低于B组（P<0.01）；A组胃肠道反应发生率显著更低（P<0.01）。
长期应用PTS对预防卒中复发、降低胃肠道不良反应及改善卒中患者神经功能有作用。与阿司匹林联合应用，在临床卒中二级预防中显示出潜在的实际意义。
